AstraZeneca loses German court appeal over Seroquel XR drug patent
Reuters
Published Jan 13, 2015 17:06
AstraZeneca loses German court appeal over Seroquel XR drug patent
KARLSRUHE, Germany (Reuters) - Britain's AstraZeneca Plc (L:AZN) on Tuesday lost an appeal in Germany's Federal Court against generic drugmakers selling cheap copies of its anti-psychotic drug Seroquel XR.
In November 2012, the federal patent court in Germany ruled a key patent on Seroquel XR, the extended-release version of Seroquel, was invalid.
The British drugmaker appealed that decision in the higher Federal Court, claiming its patent on the drug for treatment of schizophrenia, bipolar disorder and depression was valid until 2017.
The German patent had been challenged by generic drugmakers Teva Pharmaceutical Industries (TA:TEVA), Novartis's (VX:NOVN) Hexal unit and Accord Healthcare Ltd.
AstraZeneca confirmed in a statement on Tuesday it had lost the German case, adding it was disappointed with the court's decision.
According to the generic drugmakers' lawyers, existing copycat versions will now remain on the German market and more generic versions can be launched.
AstraZeneca posted global sales of $1.34 billion from both the standard release and extended release versions of Seroquel in 2013, down 12 percent from a year earlier, hurt by the loss of exclusivity in several major markets.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.